NASDAQ: FBLGFibrobiologics Inc Stock
$0.83+0.10 (+13.7%)
Updated Jun 26, 2026
FBLG Price
$0.83
Fair Value Price
$1.11
Market Cap
$4.30M
52 Week Low
$0.73
52 Week High
$14.64
P/E
-0.12x
P/B
1.65x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$18.68M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.28
Operating Cash Flow
-$15M
Beta
0.32
Next Earnings
Jul 30, 2026
Ex-Dividend
N/A
Next Dividend
N/A
FBLG Overview
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FBLG's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important FBLG news, forecast changes, insider trades & much more!
FBLG News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FBLG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FBLG ($0.83) is undervalued by 25.75% relative to our estimate of its Fair Value price of $1.11 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
FBLG ($0.83) is significantly undervalued by 25.75% relative to our estimate of its Fair Value price of $1.11 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
FBLG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FBLG due diligence checks available for Premium users.
Valuation
FBLG fair value
Fair Value of FBLG stock based on Discounted Cash Flow (DCF)
Price
$0.83
Fair Value
$1.11
Undervalued by
25.39%
FBLG ($0.83) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FBLG ($0.83) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FBLG is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FBLG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
16.11x
Market
12.38x
FBLG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.65x
Industry
5.36x
FBLG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FBLG's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.0M
Profit Margin
0%
FBLG's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$5.9M
Liabilities
$3.3M
Debt to equity
1.28
FBLG's short-term assets ($2.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FBLG's short-term assets ($2.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FBLG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.4M
Investing
$0.0
Financing
$952.0k
FBLG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FBLG vs Biotech Stocks
Fibrobiologics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.